TG Therapeutics share price logo

TG Therapeutics

NASDAQ: TGTX

Mid Cap

$50.56

-1.12

(-2.18%)

as on

TG Therapeutics Stock Performance

as on August 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $50.54
    $53.18
    downward going graph

    0.04%

    Downside

    5.18%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $26.76
    $59.30
    downward going graph

    47.07%

    Downside

    17.29%

    Upside

    downward going graph

TG Therapeutics share price movements today

Previous Close
$51.69
Open
$51.73
Volume
2.1M
Market Cap
$7.5B
Day's Low - High
$50.54 - $53.18
52 Week Low - High
$26.76 - $59.30

TG Therapeutics Historical Returns

1 Month Return
-11.17 %
3 Month Return
+ 23.39 %
1 Year Return
+ 73.58 %
3 Year Return
+ 369.1 %
5 Year Return
+ 118.57 %

TG Therapeutics Stock Fundamentals & Key Indicators

Check TG Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.5B

EPS (TTM)

3.0449

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.71%

PE Ratio (TTM)

15.74

Industry PE ratio

-13.046547619047619

PEG Ratio

0.024544438640589195

EBITDA

134.2M

Revenue (TTM)

799.5M

Profit Margin

82.36%

Return On Equity TTM

72.30%

TG Therapeutics Stock Valuation

Track how TG Therapeutics P/E has moved over time to understand its valuation trends.

TG Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-7.22x)

December 31, 2021

Industry (-13.05x)

December 31, 2025

Today (9.62x)

December 31, 2025

Highest (191.33x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: 9.62x

TG Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of TG Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$7.5B118.57%15.7482.36%NA
BUY$43.7B669.3%NA0.00%NA
BUY$128.2B154.86%29.8286.04%NA
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for TG Therapeutics Stock including INR - Dollar returns

The TG Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

TG Therapeutics investment value today

Current value as on today

₹1,98,011

Returns

₹98,011

(+98.01%)

Returns from TG Therapeutics Stock

₹80,057 (+80.06%)

Dollar Impact

₹17,954 (+17.95%)

Analyst Recommendation on TG Therapeutics Stock

Based on 7 analysts

BUY

71.43%

Buy

14.29%

Hold

14.29%

Sell

Based on 7 analysts, 71.42857142857143% of analysts recommend a 'BUY' rating for TG Therapeutics. Average target price of $69.71

TG Therapeutics Share Price Target

Get share price movements and forecasts by analysts on TG Therapeutics.

What analysts predicted

27.47%UPSIDE

Target Price

$69.71

Current Price

$50.56

Analyzed by

7 Analysts

Target

$69.71

TG Therapeutics target price $69.71, a slight upside of 27.47% compared to current price of $50.56. According to 7 analysts rating.

Indian Investors' Interest in TG Therapeutics Stock

Search interest for TG Therapeutics Stock has decreased by -35% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-35% versus previous 30 day period

TG Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
63
73
83
108
120
141
161
192
204
240
Gross Profit
57
65
74
92
105
122
133
154
171
199
Operating Income
-9
8
12
29
8
34
29
50
34
21
EBITDA
-8
10
15
32
12
37
32
51
28
21
Interest Expense
2
3
10
7
6
6
6
6
7
16
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-10
6
4
25
5
30
25
45
20
10
Income Tax Expense
0
0
0
2
0
2
-364
22
0
2
Net Income
-10
6
3
23
5
28
390
23
19
7
Net Profit Margin
91.30%
88.70%
88.86%
85.77%
87.14%
86.58%
82.59%
80.19%
83.65%
82.86%

TG Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
0
0
6
2
233
329
616
Gross Profit
0
0
0
0
5
2
219
290
515
Operating Income
-118
-174
-169
-273
-344
-218
20
41
123
EBITDA
-118
-173
-167
-272
-341
-213
26
49
134
Interest Expense
1
1
5
6
5
10
12
24
26
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-118
-173
-172
-279
-348
-223
13
25
107
Income Tax Expense
0
0
-
-
-
-
0
2
-339
Net Income
-118
-173
-172
-279
-348
-223
12
23
447
Net Profit Margin
45.95%
42.11%
100.00%
100.00%
88.19%
90.48%
93.95%
88.30%
83.66%

TG Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-10
6
3
23
5
28
390
23
19
27
Operating Cash Flow
-8
5
-12
-25
-28
7
-23
19
-17
21
Investing Cash Flow
-9
1
-9
15
-12
-3
46
-15
-9
-8
Financing Cash Flow
0
0
134
-6
-6
-6
-78
1
390
390
Change in Cash
-17
7
112
-15
-47
-2
-55
5
363
403

TG Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-118
-173
-172
-279
-348
-198
12
23
447
Operating Cash Flow
-93
-128
-132
-214
-295
-176
-31
-40
-24
Investing Cash Flow
-8
1
0
-24
0
-20
-50
-1
13
Financing Cash Flow
133
113
204
679
41
0
72
128
-89
Change in Cash
31
-14
70
440
-254
-196
-9
86
-100

Mutual Funds that own TG Therapeutics Stock

Check out the Mutual Funds with significant holdings in TG Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.680736%
11756830
TIAA-CREF Funds
1.075698%
1646561
Fidelity Salem Street Trust
1.023731%
1567016
Fidelity Concord Street Trust
0.899671%
1377119
VANGUARD EXPLORER FUND
0.851432%
1303280

Global Institutional Holdings in TG Therapeutics

Funds
Holdings
iShares
10.01%
Vanguard
8.53%
SPDR
3.11%
First Trust
1.28%
Michael Rockefeller
0.47%

TG Therapeutics News & Key Events

  • img

    Today's Timeline - 14 January

    Wed, 08:22 PM

    -

    TG Therapeutics reports preliminary 2025 revenue of $616 million, shares rise 11.6% to $31.10.

Insights on TG Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 11 quarters, 43.97M → 240.33M (in $), with an average increase of 15.4% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, TGTX stock has moved up by 6.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 618.6% return, outperforming this stock by 220.1%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 488.4% return, outperforming this stock by 408.7%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, 390.89M → 7.78M (in $), with an average decrease of 56.3% per quarter

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
OrganisationTG Therapeutics
Headquarters3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560
IndustryBiotechnology
CEOMr. Michael S. Weiss Esq., J.D.
E-voting on sharesClick here to vote

Key Management of TG Therapeutics

Name

Title

Mr. Michael S. Weiss Esq., J.D.

Chairman, CEO & President

Mr. Sean A. Power CPA

CFO, Corporate Secretary & Treasurer

Ms. Jenna Bosco

Senior Vice President of Corporate Communications

Mr. Adam Waldman

Chief Commercialization Officer

FAQs

What is TG Therapeutics share price today?

TG Therapeutics share price today is $50.56 as on at the close of the market. TG Therapeutics share today touched a day high of $53.18 and a low of $50.54.

What is the 52 week high and 52 week low for TG Therapeutics share?

TG Therapeutics share touched a 52 week high of $59.30 on and a 52 week low of $26.76 on . TG Therapeutics stock price today i.e. is closed at $50.56,which is 14.74% down from its 52 week high and 88.94% up from its 52 week low.

What is TG Therapeutics's market capitalisation today?

TG Therapeutics market capitalisation is $0.01T as on .

How to invest in TG Therapeutics Stock (TGTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for TG Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in TG Therapeutics Shares that will get you 0.0297 shares as per TG Therapeutics share price of $50.56 per share as on August 21, 2026 at 1:29 am IST.

What is the minimum amount required to buy TG Therapeutics Stock (TGTX) from India?

Indian investors can start investing in TG Therapeutics (TGTX) shares with as little as ₹95.695 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.95 in TG Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on TG Therapeutics share’s latest price of $50.56 as on August 21, 2026 at 1:29 am IST, you will get 0.1978 shares of TG Therapeutics. Learn more about fractional shares .

What are the returns that TG Therapeutics has given to Indian investors in the last 5 years?

TG Therapeutics stock has given 118.57% share price returns and 28.59% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?